



European Cancer Patient Coalition

GOLUP Event

Best practices for patient safety: An EU-wide view on the use of medicines off-label



Dear member,

We are writing on behalf of the Coalition supporting the [Declaration on Good Off-Label Use Practice](#) (or GOLUP Declaration), this Declaration was created in 2017 to develop a homogeneous regulatory framework on the use of off-label medicines

Off-label use is defined as the practice of using a medicine outside its authorised indication. It plays an important part in some medical areas, since it can be of benefit to patients when no other treatment option is available, such as it is often the case in rare diseases, child and adolescent care but also in areas such as cancer or mental disorders.

The GOLUP Declaration recommends that off-label use of medicinal products should only occur if a number of defined criteria are met. These criteria, drawn together by independent experts, stem from decades of research and clinical practice and serve to provide a clear framework on when and how the off-label use of medicinal products could safely take place.

Since the launch of the declaration, the GOLUP Declaration was promoted in several phases and steps that have allowed the guidelines to be disseminated, through a series of initiatives and events, such as during its Launch event in the European Parliament in 2016, the [Virtual workshop on the off-label use of medicines in Sweden and Norway](#) held in November 2020 or the recent digital event on [Patient Safety and Informed Consent: The Importance of Good Off-label Use Practices](#).

Declaration on Good Off-Label Use Practice

As mentioned, the **“Declaration for Good Off-Label Use Practice”** is supported by a [coalition of European organisations](#) that are dedicated to ensuring that high standards of patient care are upheld and that progress in medical research and innovation is achieved.

The European Brain Council -with its allied partners- **is planning to organise an event on 30 November 2021 from 14:30 to 16:00 CET on the topic where we would like to invite you to speak.** The purpose of this new digital event is to bring together patients, clinicians and policymakers to ensure greater awareness of the use of medicines off-label through the exchange of ideas and best practices from different European countries. **In case you are interested on participating on the event, please send an email to ainalaura.errando@ecpc.org before Friday, 19th November 2021 at 12:00h CET.**

To find out more about the initiative, we invite you to [download the statement](#) and visit

the [website](#).

We would like to sincerely thank you for your kind consideration. Should you require any further information, please do not hesitate to contact us.

Best regards,

ECPC team.



Copyright © 2021 European Cancer Patient Coalition, All rights reserved.

You are receiving this email because you are an ECPC Member.

Our mailing address is:

European Cancer Patient Coalition
Avenue des Arts, 6
Brussels 1210
Belgium

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
European Cancer Patient Coalition · Avenue des Arts 6 · Brussels 1210 · Belgium